ArticleFrontiers in microbiology2025
Characterization of gut microbiome dysbiosis in calcium oxalate stone patients with comorbid metabolic syndrome.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breed-dependent differences in gut microbiota linked to indole and skatole levels in Hezuo and DLY pigs.BMC microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Metabolic syndrome is an important risk factor for calcium oxalate stone, yet the underlying mechanism remain unclear. Gut microbiota is involved in human metabolic processes and is associated with both metabolic syndrome and calcium oxalate stone formation. Methods: In this study, 100 subjects were divided into four groups: calcium oxalate stone with metabolic syndrome (Group A), metabolic syndrome only (Group B), calcium oxalate stone only (Group C), and healthy controls (Group D), with 25 cases in each group. Gut microbiota composition and function were analyzed using Results: The α diversity in Group A was significantly lower than in the other three groups (Shannon index, Conclusion: Patients with calcium oxalate stone and metabolic syndrome exhibit a "double imbalance" in gut microbiota: on the one hand, the reduced diversity of the microbiota and the decrease of SCFAs-producing microbiota weakened the metabolic protective effect of the gut microbiota; on the other hand, the enrichment of pro-inflammatory and pathogenic bacteria exacerbated metabolic disorders and inflammatory reactions. The present study reveals that gut microbiota play a role in the mechanism of metabolic syndrome promoting calcium oxalate stone formation, and these findings provide a theoretical basis for the use of probiotics to prevent calcium oxalate stone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.